Perspectives
"Investment in biologics based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment options, higher returns on investment and slower erosion of market share post patent expiry compared to small molecule based drugs.
See our 20 pg report, "Ever Greening” To Remain Evergreen: Evolution of Antibody Technology to Drive M&A", for further details.
" ... Read more
6 Jan 2010 | From the latest Perspectives entry by Subita Srimal, Developing “Better Biologics” through "Evergreening "= High Value Proposition
Research Library . Recent Updates
| 5 Mar 2010 | RANBAXY, Not Rated - Selling of Exclusivities - Is this the Beginning » |
|---|---|
| 4 Mar 2010 | Sanofi-Aventis, Abraxis Bioscience, Genta Incorporated - Cabazitaxel - Impressive data in HRPC » |
| 4 Mar 2010 | INTERMUNE, Outperform - A Positive Verdict… » |
| 4 Mar 2010 | SHIONOGI, Positive Investment Alert - In-licensing Ospemifene, Fair Probability to Reach Market » |
| 2 Mar 2010 | RDEA, REGN, NVS, Takeda - Outperform; MRK, SVNT, XOMA - Market Perform: Therapeutic Class Overview: Gout » |
| 26 Feb 2010 | RIGL - Outperform: A Long Term Buy » |
